Embodied AI Program

Embodied AI Research Briefs

Opportunity assessments across five scale tiers — from planetary systems to molecular machines.

Published Briefs

Research direction assessments

Each brief evaluates a research direction for scientific merit, technical readiness, team fit, and funding viability.

DECI TRL 4 April 13, 2026

Autonomous Closed-Loop Bioelectronic Wound Dressings for Chronic Wound Therapy

Four independent research groups (Caltech, Stanford, UC Santa Cruz, University of Arizona) have demonstrated field-validated prototypes achieving closed-loop healing acceleration and ML-based wound classification comparable to expert clinicians in a 20-patient human trial. Zero commercial products combine real-time wound biomarker monitoring with autonomous closed-loop drug delivery. The US has 8.2 million Medicare beneficiaries with chronic wounds generating $28 billion in annual spending.

Read Brief
Embodied AI
HECTO TRL 4 April 6, 2026

DRL-Guided Autonomous Structural Crack Inspection for Steel Bridge Fatigue Prognosis

Three independent groups have demonstrated field-validated prototypes achieving 59.6% inspection time reduction, 85% autonomous crack detection rates, and 3x faster data collection. Zero commercial products combine DRL-guided autonomous crack exploration with finite-element digital twin fatigue life prediction. The US has 617,000 bridges requiring biennial inspection, with 42,067 rated structurally deficient. The Infrastructure Investment and Jobs Act committed $40 billion to bridge investment.

Read Brief
Embodied AI
CENTI TRL 4 March 30, 2026

Autonomous In-Pipe Robots for Drinking Water Infrastructure Condition Assessment

Four independent systems (Pipebots at Sheffield, MIT Mechatronics, SubMerge in Netherlands, MotBot at Motmot Inc.) have demonstrated tetherless in-pipe robots in water distribution networks. Zero commercial products exist for autonomous inspection of live pressurized drinking water mains. The gap between demonstrated prototypes and utility-scale deployment — multi-sensor fusion, miniaturized manufacturing, and utility data integration — represents a first-mover opportunity in a $1.37B annual recurring US market.

Read Brief
Embodied AI
DECA TRL 5 March 23, 2026

Self-Driving Laboratories for Autonomous Materials Discovery

Three independent systems (A-Lab at Berkeley, Polybot at Argonne, MINERVA at BAM) have demonstrated continuous autonomous materials synthesis. Zero commercial SDL products exist. The DOE committed $320M through the Genesis Mission (December 2025). The gap between validated prototypes and deployable products — scalable active learning algorithms, modular hardware integration, and manufacturing scale-up — represents a first-mover opportunity in a $5.7B US market.

Read Brief
Embodied AI
MESO TRL 5 March 16, 2026

RL-Adaptive Rehabilitation Exoskeletons for Post-Stroke Gait Recovery

Four independent groups have demonstrated 24% metabolic cost reductions using reinforcement learning on hip and ankle exoskeletons (Nature 2022, 2024). Zero commercial rehabilitation exoskeletons use RL-adaptive control — all FDA-cleared devices operate with fixed, pre-programmed gait trajectories. The gap between demonstrated RL performance and clinical deployment represents a first-mover opportunity in a device class where Medicare reimbursement already exists.

Read Brief
Embodied AI
MESO TRL 4 March 14, 2026

Autonomous Soft Tissue Surgical Systems with Learned Dexterity

All 53 FDA-cleared surgical robots operate at Level 1-3 autonomy — the surgeon performs every action. Recent demonstrations of Level 4 autonomy in soft tissue (Johns Hopkins STAR, SRT-H) show that imitation learning from surgical video can achieve superhuman precision in specific procedures. No commercial entity is pursuing Level 4 surgical autonomy.

Read Brief
Embodied AI
MICRO TRL 4 March 13, 2026

Closed-Loop Adaptive Bioelectronic Implants for Inflammatory Disease

Autoimmune and chronic inflammatory diseases affect over 24 million Americans. Current immunosuppressive therapies carry severe side effects and lose efficacy over time. Bioelectronic medicine offers a fundamentally different approach: precisely timed electrical stimulation of the vagus nerve to modulate the cholinergic anti-inflammatory pathway.

Read Brief
Embodied AI
Published Research

Open-source simulation platforms

Reinforcement learning environments for safety-critical medical applications. All packages available on PyPI with comprehensive test suites.

1
AnestheSim — RL environments for automated anesthesia drug dosing (109 tests)
2
NeuroSim — RL platform for brain-computer interfaces (158 tests)
3
VascularSim — Microbot navigation in patient-derived vascular networks (139 tests)
4
PeptideGym — RL environments for therapeutic peptide design (125 tests)
5
OncoSim — RL for radiation therapy treatment planning (141 tests)
6
GlucoSim — RL for glucose management in Type 1 diabetes (117 tests)
7
VentiSim — RL for mechanical ventilation control (230 tests)
8
CardioSim — RL for cardiac electrophysiology (134 tests)

Research originally published by Smart Technology Investments Research Institute (smarttechinvest.com/research). Licensed to H.H.A. Applied Research Institute under a non-exclusive research license for R&D and grant pursuit. Commercial exploitation rights retained by STI.